MCID: THY009
MIFTS: 50

Thyroid Lymphoma

Categories: Blood diseases, Rare diseases, Cancer diseases, Immune diseases, Endocrine diseases

Aliases & Classifications for Thyroid Lymphoma

Summaries for Thyroid Lymphoma

MalaCards based summary : Thyroid Lymphoma is related to thyroiditis and lymphoma, and has symptoms including dysphagia, respiratory distress and lymphadenopathy. An important gene associated with Thyroid Lymphoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Regulation of TP53 Activity and Apoptosis Modulation and Signaling. The drugs rituximab and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include thyroid, b cells and liver, and related phenotypes are endocrine/exocrine gland and hematopoietic system

Wikipedia : 72 Thyroid lymphoma is a rare malignant tumor constituting 1% to 2% of all thyroid malignancies and less... more...

Related Diseases for Thyroid Lymphoma

Diseases related to Thyroid Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
id Related Disease Score Top Affiliating Genes
1 thyroiditis 10.6
2 lymphoma 10.6
3 cd3epsilon deficiency 10.4 IL7 IL7R
4 cervical benign neoplasm 10.4 FAS TP53
5 cervical adenoid cystic carcinoma 10.4 CDKN2A TP53
6 split hand split foot nystagmus 10.4 CDKN2A TP53
7 leiomyoma cutis 10.4 CDKN2A TP53
8 anal squamous cell carcinoma 10.4 CDKN2A TP53
9 rectum squamous cell carcinoma 10.4 CDKN2A TP53
10 breast myoepitheliosis 10.4 CDKN2A TP53
11 ritter's disease 10.4 CDKN2A TP53
12 coccidiosis 10.4 CDKN2A TP53
13 adenocarcinoma in situ 10.4 CDKN2A TP53
14 penis paget's disease 10.4 CDKN2A TP53
15 retinal detachment 10.4 CDKN2A TP53
16 larynx carcinoma in situ 10.4 CDKN2A TP53
17 phalanx chondroma 10.4 CDKN2A TP53
18 olfactory neural tumor 10.4 CDKN2A TP53
19 orbital lymphoma 10.3 CDKN2A TP53
20 non-suppurative otitis media 10.3 CDKN2A TP53
21 pancreatic agenesis 10.3 CDKN2A TP53
22 secondary pulmonary hemosiderosis 10.3 CDKN2A TP53
23 opitz-kaveggia syndrome 10.3 IL7 IL7R
24 villous adenocarcinoma 10.3 CDKN2A TP53
25 multiple carboxylase deficiency 10.3 CDKN2A TP53
26 spastic ataxia 3 10.3 CDKN2A TP53
27 esophagus squamous cell carcinoma 10.3 CDKN2A TP53
28 pediatric osteosarcoma 10.3 CDKN2A TP53
29 bladder squamous cell carcinoma 10.3 CDKN2A TP53
30 advanced sleep phase syndrome 10.3 CDKN2A TP53
31 plasmodium ovale malaria 10.3 CDKN2A TP53
32 internal auditory canal lipoma 10.3 CDKN2A TP53
33 middle ear squamous cell carcinoma 10.3 CDKN2A TP53
34 childhood oligodendroglioma 10.3 CDKN2A TP53
35 c-p angle neurinoma 10.3 CDKN2A TP53
36 vestibular disease 10.3 CDKN2A TP53
37 secondary hyperparathyroidism of renal origin 10.3 CDKN2A TP53
38 molluscum contagiosum 10.3 CDKN2A TP53
39 schwannian stroma-rich and stroma-poor composite ganglioneuroblastoma 10.3 CDKN2A TP53
40 gastrointestinal neuroendocrine tumor 10.3 CDKN2A TP53
41 ductal carcinoma in situ 10.2 CDKN2A TP53
42 cecum adenocarcinoma 10.2 CDKN2A TP53
43 pancreatoblastoma 10.2 CDKN2A TP53
44 choriocarcinoma 10.2 CDKN2A TP53
45 rare endometriosis 10.2 CDKN2A TP53
46 exertional headache 10.2 CDKN2A FAS
47 myxedema 10.2 CDKN2A TP53
48 embryonal rhabdomyosarcoma 10.2 CDKN2A TP53
49 unilateral retinoblastoma 10.2 CDKN2A TP53
50 anaerobic pneumonia 10.2 CDKN2A TP53

Graphical network of the top 20 diseases related to Thyroid Lymphoma:



Diseases related to Thyroid Lymphoma

Symptoms & Phenotypes for Thyroid Lymphoma

Human phenotypes related to Thyroid Lymphoma:

56 32 (show all 14)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dysphagia 56 32 frequent (33%) Frequent (79-30%) HP:0002015
2 respiratory distress 56 32 very rare (1%) Very rare (<4-1%) HP:0002098
3 lymphadenopathy 56 32 frequent (33%) Frequent (79-30%) HP:0002716
4 goiter 56 32 obligate (100%) Obligate (100%) HP:0000853
5 hyperthyroidism 56 32 occasional (7.5%) Occasional (29-5%) HP:0000836
6 hypothyroidism 56 32 frequent (33%) Frequent (79-30%) HP:0000821
7 broad neck 56 32 hallmark (90%) Very frequent (99-80%) HP:0000475
8 lymphoma 56 32 obligate (100%) Obligate (100%) HP:0002665
9 stridor 56 32 frequent (33%) Frequent (79-30%) HP:0010307
10 hashimoto thyroiditis 56 32 frequent (33%) Frequent (79-30%) HP:0000872
11 upper airway obstruction 56 32 frequent (33%) Frequent (79-30%) HP:0002781
12 hoarse voice 56 32 frequent (33%) Frequent (79-30%) HP:0001609
13 pain 56 32 occasional (7.5%) Occasional (29-5%) HP:0012531
14 dyspnea 56 Frequent (79-30%)

MGI Mouse Phenotypes related to Thyroid Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.8 FAS IL7 IL7R TP53 TP73 CDKN2A
2 hematopoietic system MP:0005397 9.8 FAS IL7 IL7R PICALM TP53 TP73
3 immune system MP:0005387 9.7 FAS IL7 IL7R PICALM TP53 TP73
4 neoplasm MP:0002006 9.35 IL7R TP53 TP73 CDKN2A FAS
5 pigmentation MP:0001186 8.92 FAS PICALM TP53 CDKN2A

Drugs & Therapeutics for Thyroid Lymphoma

Drugs for Thyroid Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2 174722-31-7 10201696
2
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
6
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
7 Antibodies Phase 4,Phase 3,Phase 2
8 Antiemetics Phase 4,Phase 2
9 Antimetabolites Phase 4,Phase 2,Phase 1
10 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 1
11 Antirheumatic Agents Phase 4,Phase 3,Phase 2
12 Autonomic Agents Phase 4,Phase 2
13 Dermatologic Agents Phase 4,Phase 2
14 Gastrointestinal Agents Phase 4,Phase 2
15 Immunoglobulins Phase 4,Phase 3,Phase 2
16 Immunosuppressive Agents Phase 4,Phase 2
17 Peripheral Nervous System Agents Phase 4,Phase 2
18 Protective Agents Phase 4,Early Phase 1
19 Anti-Inflammatory Agents Phase 4
20 Antineoplastic Agents, Hormonal Phase 4
21 Folic Acid Antagonists Phase 4
22 glucocorticoids Phase 4
23 Hormone Antagonists Phase 4
24 Hormones Phase 4
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
26 Methylprednisolone acetate Phase 4
27 Methylprednisolone Hemisuccinate Phase 4
28 Neuroprotective Agents Phase 4
29 Nucleic Acid Synthesis Inhibitors Phase 4
30 Prednisolone acetate Phase 4
31 Prednisolone hemisuccinate Phase 4
32 Prednisolone phosphate Phase 4
33 Vitamin B Complex Phase 4
34 Folate Nutraceutical Phase 4
35 Vitamin B9 Nutraceutical Phase 4
36
Iodine Investigational Phase 3,Phase 2,Early Phase 1 7553-56-2 807
37 Antibodies, Monoclonal Phase 3,Phase 2
38 Anti-Infective Agents Phase 3,Phase 2
39 Anti-Infective Agents, Local Phase 3,Phase 2
40 cadexomer iodine Phase 3,Phase 2,Early Phase 1
41 Iodine-131 anti-B1 antibody Phase 3,Phase 2
42 Micronutrients Phase 3,Phase 2
43 Trace Elements Phase 3,Phase 2
44 Fluorodeoxyglucose F18 Phase 2, Phase 3
45 Radiopharmaceuticals Phase 2, Phase 3
46
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
47
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
48
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
49
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
50
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978

Interventional clinical trials:

(show all 38)

id Name Status NCT ID Phase Drugs
1 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
2 Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma Completed NCT00268983 Phase 3
3 Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer Completed NCT00123760 Phase 2, Phase 3
4 Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma. Recruiting NCT02964858 Phase 3
5 Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody Completed NCT00938041 Phase 2
6 Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma Completed NCT00268203 Phase 2
7 A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL) Completed NCT01573000 Phase 2
8 Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP Completed NCT01868035 Phase 2 tositumomab and iodine I-131 tositumomab
9 A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) Completed NCT00923247 Phase 1, Phase 2 Bortezomib;Vandetanib
10 Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab Completed NCT00996593 Phase 2
11 Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma Completed NCT00992992 Phase 2
12 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2 Fostamatinib disodium
13 Phase 2 Study of Bexxar in Relapsed/Refractory DLCL Completed NCT00490009 Phase 2 Bexxar;Acetaminophen;Diphenhydramine;Potassium Iodide (KI)
14 Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma Completed NCT00996996 Phase 2
15 Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab Completed NCT00933335 Phase 2
16 Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Completed NCT00950755 Phase 2
17 Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Completed NCT00896454 Phase 2 denosumab
18 NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma Recruiting NCT02465060 Phase 2 Afatinib;Akt inhibitor AZD5363;Binimetinib;Crizotinib;Dabrafenib;Dasatinib;Defactinib;FGFR Inhibitor AZD4547;Larotrectinib;Osimertinib;Palbociclib;PI3K-beta Inhibitor GSK2636771;Sapanisertib;Sunitinib Malate;Taselisib;Trametinib;Vismodegib;WEE1 Inhibitor AZD1775
19 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Recruiting NCT02568267 Phase 2 Entrectinib
20 Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer Suspended NCT02152137 Phase 2 efatutazone;paclitaxel
21 Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies Completed NCT00215605 Phase 1 XL184
22 Depsipeptide to Treat Thyroid and Other Advanced Cancers Completed NCT00048334 Phase 1 Depsipeptide, FR901228, FK228
23 Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma Completed NCT00413075 Phase 1 oral belinostat
24 Spectroscopy With Surface Coils and Decoupling Completed NCT00581815 Phase 1
25 Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Recruiting NCT01638533 Phase 1 Romidepsin
26 Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies Recruiting NCT02223052 Phase 1 CC-486;Vidaza
27 Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma Not yet recruiting NCT03291938 Phase 1 IACS-010759
28 11C-Acetate PET/CT Non-FDG-Avid Tumors Unknown status NCT00687778
29 Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers Completed NCT00342641
30 A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression Completed NCT00718770 Early Phase 1 Bexarotene
31 B-Receptor Signaling in Cardiomyopathy Completed NCT01135849
32 The Effect of Human Placental Explants and Pregnant Women Sera on Cancer Cells Recruiting NCT01879436
33 PET Imaging of Patients Using 124I-PU-AD Recruiting NCT02751554 124I-PU-AD
34 10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus Recruiting NCT00568997 Pimecrolimus
35 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford Recruiting NCT01793168
36 Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes Active, not recruiting NCT01664936
37 Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy Active, not recruiting NCT02062632 Doxepin Hydrochloride
38 Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia Withdrawn NCT01688752

Search NIH Clinical Center for Thyroid Lymphoma

Genetic Tests for Thyroid Lymphoma

Anatomical Context for Thyroid Lymphoma

MalaCards organs/tissues related to Thyroid Lymphoma:

39
Thyroid, B Cells, Liver, Lung, Testes, Colon, Lymph Node

Publications for Thyroid Lymphoma

Articles related to Thyroid Lymphoma:

(show top 50) (show all 186)
id Title Authors Year
1
Primary thyroid lymphoma: a rare but challenging diagnosis. ( 28581452 )
2017
2
Preoperative diagnostic algorithm of primary thyroid lymphoma using ultrasound, aspiration cytology, and flow cytometry. ( 28690277 )
2017
3
Primary thyroid lymphoma: A case report and review of the literature. ( 28053701 )
2017
4
Diagnosis and Clinical Analysis of Primary Thyroid Lymphoma. ( 28695809 )
2017
5
Residual FDG uptake of primary thyroid lymphoma after treatment may overestimate residual lymphoma. ( 27614754 )
2016
6
Primary thyroid lymphoma. ( 26985163 )
2016
7
Primary Thyroid Lymphoma: Clinicopathologic Characteristics and Therapeutic Outcomes of Six Cases in Morocco. ( 28191800 )
2016
8
Efficacy of Fine-Needle Aspiration Cytology in the Diagnosis of Primary Thyroid Lymphoma for Elderly Adults. ( 27557116 )
2016
9
Pathology Verified Concomitant Papillary Thyroid Carcinoma in the Sonographically Suspected Thyroid Lymphoma: A Case Report. ( 28031089 )
2016
10
Development of Primary Thyroid Lymphoma during an Ultrasonographic Follow-up of Hashimoto's Thyroiditis: A Report of 9 Cases. ( 27086809 )
2016
11
Wnt5a and Ror2 expression associate with the disease progress of primary thyroid lymphoma. ( 26614433 )
2016
12
Clinical Presentation and Diagnostic Challenges of Thyroid Lymphoma: A Cohort Study. ( 27256107 )
2016
13
Wnt5a and Ror2 expression associate with the disease progress of primary thyroid lymphoma. ( 26608372 )
2016
14
Primary thyroid lymphoma presenting as dermatomyositis: a first case and review of the literature. ( 27126096 )
2016
15
Complete resolution of autoimmune thyroiditis after R-CHOP in a patient with thyroid lymphoma. ( 26687264 )
2015
16
Evaluation of primary thyroid lymphoma by ultrasonography combined with contrast-enhanced ultrasonography: A pilot study. ( 26960472 )
2015
17
Primary thyroid lymphoma: The two ends of the spectrum. ( 26416071 )
2015
18
Primary thyroid lymphoma has different sonographic and color Doppler features compared to nodular goiter. ( 25614405 )
2015
19
Clinicopathological characteristics and treatment outcomes of 38 cases of primary thyroid lymphoma: a multicenter study. ( 26665123 )
2015
20
12 cases of primary thyroid lymphoma in China. ( 25736543 )
2015
21
Core needle biopsy could reduce diagnostic surgery in patients with anaplastic thyroid cancer or thyroid lymphoma. ( 26201291 )
2015
22
Hoarseness: an unusual presentation of primary thyroid lymphoma with laryngeal infiltration. ( 26411267 )
2015
23
Primary thyroid lymphoma: multi-slice computed tomography findings. ( 25735344 )
2015
24
Hypothyroidism after radiotherapy for primary thyroid lymphoma. ( 25075081 )
2014
25
Rituximab-including combined modality treatment for primary thyroid lymphoma: an effective regimen for elderly patients. ( 24547778 )
2014
26
Sonographic appearance of primary thyroid lymphoma-preliminary experience. ( 25474402 )
2014
27
Primary thyroid lymphoma: case series with review of literature. ( 25332615 )
2014
28
Identification of primary thyroid lymphoma with medical imaging: A case report and review of the literature. ( 25364417 )
2014
29
Non-Hodgkin's thyroid lymphoma associated with Hashimoto's thyroiditis. ( 24864614 )
2014
30
Fine needle cytology and flow cytometry in hashimoto thyroiditis and primary thyroid lymphoma. ( 24642841 )
2014
31
Diagnosing thyroid lymphoma: steroid administration may result in rapid improvement of dyspnea : a report of two cases. ( 24696693 )
2014
32
Primary thyroid lymphoma: A rare disease. ( 25745292 )
2014
33
Aggressive primary thyroid lymphoma: imaging features of two elderly patients. ( 25060184 )
2014
34
Thyroid lymphoma on a background of Hashimoto's thyroiditis: PET/CT appearances. ( 24679651 )
2014
35
Primary thyroid lymphoma. ( 24935697 )
2014
36
Tracheal invasion and perforation from advanced primary thyroid lymphoma: a case report and literature review. ( 23702317 )
2013
37
Patterns of care and treatment outcomes for primary thyroid lymphoma: a single institution study. ( 24501704 )
2013
38
Ulcerative colitis associated with extranodal marginal zone B-cell thyroid lymphoma of mucosa-associated lymphoid tissue and Hashimoto thyroiditis: description of a case. ( 24714310 )
2013
39
Primary thyroid lymphoma: a series of two cases and review of literature. ( 24772759 )
2013
40
Clinicopathologic study and outcome analysis of thyroid lymphomas: experience from a tertiary cancer center. ( 22368156 )
2013
41
A rare coexistence of thyroid lymphoma with papillary thyroid carcinoma. ( 24005594 )
2013
42
Thyroid lymphoma: recent advances in diagnosis and optimal management strategies. ( 23881987 )
2013
43
Is 18F-FDG PET/CT useful for distinguishing between primary thyroid lymphoma and chronic thyroiditis? ( 23816945 )
2013
44
Thyroid lymphoma: diagnostic pitfalls on pre-operative ago-biopsy. ( 23134840 )
2013
45
Primary thyroid lymphoma: a clinical review. ( 23714679 )
2013
46
Thyroid lymphoma incidentally detected by 18F-fluorocholine (FCH) PET/CT. ( 23856826 )
2013
47
Primary thyroid lymphoma arising from Hashimotos thyroiditis diagnosed by fine needle aspiration cytology. ( 22531543 )
2012
48
Importance of core biopsy in the diagnosis of thyroid lymphoma. ( 22507512 )
2012
49
Primary thyroid lymphoma: the 40 year experience of a UK lymphoma treatment centre. ( 22367111 )
2012
50
Cytodiagnosis of primary thyroid lymphoma with histologic correlation: A case report. ( 21681970 )
2012

Variations for Thyroid Lymphoma

Expression for Thyroid Lymphoma

Search GEO for disease gene expression data for Thyroid Lymphoma.

Pathways for Thyroid Lymphoma

Pathways related to Thyroid Lymphoma according to GeneCards Suite gene sharing:

(show all 24)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.59 CCNB1 CDKN2A FAS TP53 TP73
2
Show member pathways
12.52 CDKN2A FAS TP53 TP73
3 12.39 FAS IL7 IL7R TP53
4
Show member pathways
12.19 CCNB1 FAS TP53
5 12.17 CCNB1 CDKN2A TP53 TP73
6 12.11 CCNB1 CDKN2A TP53
7
Show member pathways
12.09 CCNB1 CDKN2A TP53
8 11.73 CDKN2A TP53 TP73
9
Show member pathways
11.68 FAS TP53 TP73
10 11.68 CCNB1 FAS TP53 TP73
11 11.59 CCNB1 CDKN2A FAS TP53
12
Show member pathways
11.57 CCNB1 TP53 TP73
13 11.47 CDKN2A FAS TP53
14
Show member pathways
11.38 CCNB1 CDKN2A FAS TP53 TP73
15
Show member pathways
11.27 CCNB1 TP53
16
Show member pathways
11.25 IL7 IL7R
17 11.25 FAS TP53
18 11.21 CDKN2A FAS TP53
19 11.1 CCNB1 TP53
20 11.09 CDKN2A TP53
21 10.99 IL7 IL7R
22 10.88 CDKN2A TP53
23 10.8 CCNB1 TP53
24
Show member pathways
10.47 CDKN2A TP53 TP73

GO Terms for Thyroid Lymphoma

Biological processes related to Thyroid Lymphoma according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.84 CDKN2A FAS TP53 TP73
2 cell cycle GO:0007049 9.78 CCNB1 CDKN2A TP53 TP73
3 positive regulation of transcription, DNA-templated GO:0045893 9.76 CDKN2A PICALM TP53 TP73
4 regulation of apoptotic process GO:0042981 9.74 FAS TP53 TP73
5 immunoglobulin production GO:0002377 9.58 FAS IL7R
6 cellular response to UV GO:0034644 9.58 TP53 TP73
7 protein tetramerization GO:0051262 9.56 TP53 TP73
8 response to gamma radiation GO:0010332 9.55 TP53 TP73
9 cell cycle arrest GO:0007050 9.54 CDKN2A TP53 TP73
10 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.52 TP53 TP73
11 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.51 TP53 TP73
12 positive regulation of cell cycle arrest GO:0071158 9.49 TP53 TP73
13 response to X-ray GO:0010165 9.43 TP53 TP73
14 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.4 TP53 TP73
15 replicative senescence GO:0090399 9.32 CDKN2A TP53
16 mitotic G1 DNA damage checkpoint GO:0031571 9.26 TP53 TP73
17 positive regulation of apoptotic process GO:0043065 9.26 CDKN2A FAS TP53 TP73
18 protein complex assembly GO:0006461 8.92 CCNB1 FAS PICALM TP53
19 interleukin-7-mediated signaling pathway GO:0038111 8.85 IL7R

Molecular functions related to Thyroid Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 9.33 CDKN2A TP53 TP73
2 protein kinase binding GO:0019901 8.92 CCNB1 CDKN2A TP53 TP73
3 disordered domain specific binding GO:0097718 8.65 TP53

Sources for Thyroid Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....